Given the importance of targeting integrin-mediated retention of MCL cells in the lymphoid organ microenvironment for the clinical efficacy of ibrutinib [2–4], we next investigated whether KIN-8194 inhibits the integrin-mediated adhesion of MCL to fibronectin (FN) and the stromal cell lines HS-5 and HS-27a. Here, FN1 is linked to mantle cell lymphoma.